In our experience, B16.F10 cells, as evidenced by the tumor volume graphs, grow very aggressively, and therefore, we chose an early time point (day 1 PTC) to commence the Ad5-TRP2 vaccination treatment in the therapeutic studies. This evidence concerns the gene DCT and neoplasm.